Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA) filed a Form 8-K on February 02, 2026, reporting significant clinical trial progress and pipeline updates. The Company is an emerging growth company incorporated in Florida, with its common stock trading on The Nasdaq Capital Market under the symbol MIRA.
Key Financial Metrics
This filing is a Current Report (Item 8.01) focused on operational milestones and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Updates
- Ketamir-2 Phase 1 Progress: The Company initiated dosing in the final cohort of its Phase 1 multiple ascending dose (MAD) clinical trial for Ketamir-2, an oral NMDA receptor antagonist. To date, 50 healthy volunteers have been dosed, with 6 subjects remaining in the final cohort.
- Timeline: Completion of the Phase 1 clinical program is expected by the end of the first quarter of 2026.
- Phase 2a Planning: The Company is finalizing its Phase 2a proof-of-concept study for chemotherapy-induced peripheral neuropathy (CIPN). The protocol is planned for submission to the FDA following Phase 1 completion, with study initiation anticipated in the second quarter of 2026.
- Regulatory Strategy: MIRA intends to pursue FDA Fast Track designation for Ketamir-2 given the oncology-related nature of CIPN and the lack of approved therapies.
- Preclinical Pipeline:
- SKNY-1: An oral small-molecule for weight loss and nicotine addiction, designed to avoid CNS-related adverse effects and muscle loss. Currently undergoing CMC optimization.
- MIRA-55: A preclinical program for inflammatory pain demonstrating analgesic and anti-inflammatory activity. Currently undergoing CMC optimization.
- Upcoming Events: The Company plans to engage in partnering discussions at the BIO Summit in March 2026 and present Phase 1 data at the AACR Annual Meeting in April 2026.
Guidance, Outlook, and Risks
Management anticipates advancing SKNY-1 and MIRA-55 to IND-enabling status by year-end 2026. The filing highlights the strategic intent to seek FDA Fast Track designation for Ketamir-2. No specific financial guidance or quantified risk factors were disclosed in this specific report, though standard clinical development risks (e.g., regulatory feedback, trial outcomes) are implied by the nature of the updates.
Key Facts for Investor Verification
- Verify the exact completion date of the Phase 1 trial against the "end of Q1 2026" expectation.
- Monitor the FDA's response to the upcoming Phase 2a protocol submission for CIPN.
- Track the outcome of partnering discussions at the March 2026 BIO Summit.
- Confirm the presentation of Phase 1 data at the April 2026 AACR Annual Meeting.
- Review subsequent filings for financial updates, as this 8-K contains no financial data.